AU2020272743B2 - Pyrrolotriazine derivatives for treating KIT- and PDGFRa-mediated diseases - Google Patents

Pyrrolotriazine derivatives for treating KIT- and PDGFRa-mediated diseases

Info

Publication number
AU2020272743B2
AU2020272743B2 AU2020272743A AU2020272743A AU2020272743B2 AU 2020272743 B2 AU2020272743 B2 AU 2020272743B2 AU 2020272743 A AU2020272743 A AU 2020272743A AU 2020272743 A AU2020272743 A AU 2020272743A AU 2020272743 B2 AU2020272743 B2 AU 2020272743B2
Authority
AU
Australia
Prior art keywords
mmol
compound
pyrazol
compounds
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020272743A
Other languages
English (en)
Other versions
AU2020272743A1 (en
Inventor
Thomas A. DINEEN
Timothy Guzi
Joseph L. Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blueprint Medicines Corp
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70416596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020272743(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of AU2020272743A1 publication Critical patent/AU2020272743A1/en
Application granted granted Critical
Publication of AU2020272743B2 publication Critical patent/AU2020272743B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020272743A 2019-04-12 2020-04-08 Pyrrolotriazine derivatives for treating KIT- and PDGFRa-mediated diseases Active AU2020272743B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962833529P 2019-04-12 2019-04-12
US62/833,529 2019-04-12
US201962911016P 2019-10-04 2019-10-04
US62/911,016 2019-10-04
US201962930240P 2019-11-04 2019-11-04
US62/930,240 2019-11-04
PCT/US2020/027177 WO2020210293A1 (en) 2019-04-12 2020-04-08 Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases

Publications (2)

Publication Number Publication Date
AU2020272743A1 AU2020272743A1 (en) 2021-11-11
AU2020272743B2 true AU2020272743B2 (en) 2025-10-16

Family

ID=70416596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020272743A Active AU2020272743B2 (en) 2019-04-12 2020-04-08 Pyrrolotriazine derivatives for treating KIT- and PDGFRa-mediated diseases

Country Status (33)

Country Link
US (3) US12552795B2 (enExample)
EP (2) EP4424312A3 (enExample)
JP (2) JP7600140B2 (enExample)
KR (1) KR102875260B1 (enExample)
CN (1) CN113939515B (enExample)
AU (1) AU2020272743B2 (enExample)
BR (1) BR112021020441A2 (enExample)
CA (1) CA3136802A1 (enExample)
CL (1) CL2021002656A1 (enExample)
CO (1) CO2021015113A2 (enExample)
DK (1) DK3953357T3 (enExample)
EC (1) ECSP21080096A (enExample)
ES (1) ES2980811T3 (enExample)
FI (1) FI3953357T3 (enExample)
HR (1) HRP20240702T1 (enExample)
HU (1) HUE067299T2 (enExample)
IL (1) IL287168B2 (enExample)
LT (1) LT3953357T (enExample)
MA (1) MA55604B1 (enExample)
MD (1) MD3953357T2 (enExample)
MX (1) MX2021012469A (enExample)
MY (1) MY209048A (enExample)
PE (1) PE20212331A1 (enExample)
PH (1) PH12021552568A1 (enExample)
PL (1) PL3953357T3 (enExample)
PT (1) PT3953357T (enExample)
RS (1) RS65644B1 (enExample)
SG (1) SG11202111244XA (enExample)
SI (1) SI3953357T1 (enExample)
SM (1) SMT202400229T1 (enExample)
TW (1) TWI857043B (enExample)
WO (1) WO2020210293A1 (enExample)
ZA (1) ZA202108104B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970745B (zh) 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途
SG11202111244XA (en) 2019-04-12 2021-11-29 Blueprint Medicines Corp Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
CN117098760B (zh) * 2020-10-14 2026-04-14 缆图药品公司 用于治疗kit和pdgfra介导的疾病的组合物和方法
WO2022081626A1 (en) * 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions and methods for treating kit-and pdgfra-mediated diseases
HU231413B1 (hu) 2021-02-26 2023-08-28 Egis Gyógyszergyár Zrt. Eljárás avapritinib és intermedierek előállítására
JP7763848B2 (ja) * 2021-03-03 2025-11-04 ブループリント メディシンズ コーポレイション Ｋｉｔ－およびｐｄｇｆｒａ－媒介性疾患を治療するための化合物を製造するための合成方法および中間生成物
WO2022192558A1 (en) 2021-03-10 2022-09-15 Blueprint Medicines Corporation Salt and solid forms of a kinase inhibitor
CN117794935A (zh) * 2021-03-10 2024-03-29 缆图药品公司 激酶抑制剂的盐和固体形式
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
US20250129067A1 (en) * 2021-11-08 2025-04-24 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2024171143A1 (en) 2023-02-17 2024-08-22 Assia Chemical Industries Ltd. Salts and solid forms of elenestinib

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057873A1 (en) * 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238784A (ja) 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
IL144977A0 (en) * 1999-05-21 2002-06-30 Bristol Myers Squibb Co Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
PL219736B1 (pl) 2002-04-23 2015-07-31 Bristol Myers Squibb Co Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
UA81453C2 (en) 2003-02-27 2008-01-10 Pyrazolopyridine derivates
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
EP1755607A2 (en) 2004-04-29 2007-02-28 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PL1973910T3 (pl) 2006-01-27 2013-11-29 Shanghai hengrui pharmaceutical co ltd Pirolo[3,2-c]pirydyn-4-onowo-2-indolinonowe inhibitory kinazy białkowej
SI2041138T1 (sl) 2006-07-07 2014-08-29 Bristol-Myers Squibb Company Pirolotriazin kinazni inhibitorji
US8415340B2 (en) 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
CA2764818A1 (en) 2009-06-08 2010-12-16 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AU2011218167B2 (en) 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102040494A (zh) 2010-11-12 2011-05-04 西北师范大学 对氟苯甲醛的制备方法
WO2013004551A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
WO2018183712A1 (en) * 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh) 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
CN109970745B (zh) 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途
CR20200588A (es) 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
WO2020102095A1 (en) 2018-11-12 2020-05-22 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
PE20211756A1 (es) 2018-12-20 2021-09-07 Pfizer FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
SG11202111244XA (en) 2019-04-12 2021-11-29 Blueprint Medicines Corp Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
CN110950872A (zh) 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
CN110938077B (zh) 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
WO2022081626A1 (en) 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions and methods for treating kit-and pdgfra-mediated diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057873A1 (en) * 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit

Also Published As

Publication number Publication date
US20260138986A1 (en) 2026-05-21
CN113939515A (zh) 2022-01-14
SMT202400229T1 (it) 2024-07-09
WO2020210293A1 (en) 2020-10-15
FI3953357T3 (fi) 2024-07-15
CL2021002656A1 (es) 2022-08-26
TWI857043B (zh) 2024-10-01
CA3136802A1 (en) 2020-10-15
HUE067299T2 (hu) 2024-10-28
MY209048A (en) 2025-06-18
EP3953357A1 (en) 2022-02-16
KR102875260B1 (ko) 2025-10-23
EP4424312A2 (en) 2024-09-04
US20220153748A1 (en) 2022-05-19
IL287168B1 (en) 2025-06-01
RS65644B1 (sr) 2024-07-31
AU2020272743A1 (en) 2021-11-11
HRP20240702T1 (hr) 2024-08-16
PE20212331A1 (es) 2021-12-14
PH12021552568A1 (en) 2022-07-04
TW202104231A (zh) 2021-02-01
CN113939515B (zh) 2024-06-18
IL287168B2 (en) 2025-10-01
ZA202108104B (en) 2024-02-28
MD3953357T2 (ro) 2024-09-30
MA55604B1 (fr) 2024-08-30
KR20220025704A (ko) 2022-03-03
JP2025029094A (ja) 2025-03-05
EP4424312A3 (en) 2025-01-08
BR112021020441A2 (pt) 2021-12-14
US10829493B2 (en) 2020-11-10
PL3953357T3 (pl) 2024-09-02
US20200325141A1 (en) 2020-10-15
US12552795B2 (en) 2026-02-17
MA55604A (fr) 2022-02-16
LT3953357T (lt) 2024-07-25
EP3953357B1 (en) 2024-04-17
SG11202111244XA (en) 2021-11-29
JP2022526850A (ja) 2022-05-26
DK3953357T3 (en) 2024-06-10
SI3953357T1 (sl) 2024-08-30
IL287168A (en) 2021-12-01
CO2021015113A2 (es) 2022-02-28
ES2980811T3 (es) 2024-10-03
JP7600140B2 (ja) 2024-12-16
ECSP21080096A (es) 2022-02-25
PT3953357T (pt) 2024-07-24
MX2021012469A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
US12552795B2 (en) Pyrrolotriazine derivatives for treating kit-and PDGFRA-mediated diseases
AU2015257456B2 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EA021817B1 (ru) Кристаллический (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпиридин-4-ил)этокси)-1h-индазол-3-ил)винил)-1h-пиразол-1-ил)этанола моногидрат
CN106588937A (zh) 咪唑并吡嗪类化合物及其制备方法和应用
CN115023427A (zh) 吡唑并三嗪
CN116600808A (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
US20240299387A1 (en) Heterocyclic egfr inhibitors for use in the treatment of cancer
US20230391780A1 (en) Compositions and methods for treating kit- and pdgfra-mediated diseases
CN117098760B (zh) 用于治疗kit和pdgfra介导的疾病的组合物和方法
RU2817354C2 (ru) Композиции и способы лечения kit- и pdgfra-опосредованных заболеваний
US12258327B2 (en) 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors
HK40071629B (en) Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
HK40071629A (en) Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
US20230019732A1 (en) Egfr inhibitors
EP4377305A1 (en) Organic pyridine-pyrazole compounds and their uses
CN117715642A (zh) 杂环化合物和使用方法
CN118660705A (zh) 一种药物组合物及所含活性成分化合物的制备方法
HK1207374B (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
HK1207374A1 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)